A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
BACKGROUND Androgen receptor variant 7 (AR-V7) detection provides important reference to the clinical management of abiraterone in metastatic castration-resistant PCa (mCRPC). We performed a noninvasive urine-derived exosomal AR-V7 analysis in mCRPC patients. METHODS A total of 34 mCRPC patients were categorized into 16 patients responded to abiraterone (ABI-Sta group) and 18 were resistant to abiraterone (ABI-Res group). First morning urine collected from patients as well as healthy controldoi:10.21203/rs.3.rs-41550/v1 fatcat:ktcavmiyzngvtlythzcrid3gqe